for educational and safety purposes
Every compound in the sci-wiki that affects nmda receptor; the ones you can source are floated to the front, then the reference-only entries. Tap any for the full entry, mechanism, and outlets.
8 sourced · 16 reference
Magnesium L-threonate is a magnesium salt of L-threonic acid, a sugar acid derived from vitamin C. It was developed as a supplemental form intended to raise magnesium levels in the central nervous system more effectively than conventional magnesium salts; unlike most oral forms, it has been shown to increase magnesium in the cerebrospinal fluid and within neurons, where it up-regulates NR2B-containing NMDA receptors and increases the density of functional synapses. In animal studies these actions are associated with improved learning and enhanced retention of fear extinction, and it is studied mainly for possible effects on memory, cognition, sleep, and anxiety. First described in a 2010 laboratory study, it is sold commercially under names such as Magtein.
Pregnenolone (3β-hydroxypregn-5-en-20-one) is an endogenous neurosteroid and the first steroid synthesized from cholesterol, making it the obligatory precursor of every other steroid hormone, including progesterone, dehydroepiandrosterone (DHEA), cortisol, the sex steroids, and the neuroactive metabolites allopregnanolone and pregnenolone sulfate. Once regarded as a metabolically inert intermediate, it is now recognized as a signaling molecule in its own right, most notably as an endogenous negative allosteric modulator of the type-1 cannabinoid receptor (CB1, the principal brain receptor for THC) and as a ligand for microtubule-associated protein 2 (MAP2, a neuronal cytoskeletal scaffolding protein), through which it promotes microtubule assembly and neurite outgrowth. Synthesized de novo in the brain by neurons and glia, it is investigated as an adjunctive treatment for schizophrenia, mood disorders, and cannabis-related conditions, and is sold over the counter as a nootropic and hormonal supplement.
Agmatine is a small biogenic amine produced in the body from the amino acid arginine by the enzyme arginine decarboxylase, and it also occurs in fermented foods. Rather than acting on a single dedicated receptor, it is a neuromodulator that engages several systems at once: it is an endogenous ligand at imidazoline receptors, blocks the open pore of the NMDA glutamate receptor, and inhibits neuronal nitric oxide synthase, in part by acting as a suicide substrate that irreversibly destroys the enzyme's heme. It is studied for possible roles in pain, mood, opioid tolerance, and neuroprotection, and is sold as a dietary supplement in the form of agmatine sulfate.
Dehydroepiandrosterone (DHEA) is an endogenous androstane neurosteroid and the most abundant circulating steroid hormone in humans, secreted chiefly by the adrenal cortex and also synthesized de novo within the central nervous system. It functions primarily as a precursor to androgens and estrogens, yet exerts direct actions on the brain by acting as an agonist at the sigma-1 receptor (an endoplasmic reticulum chaperone protein that shapes calcium and neurotrophic signaling), as a positive modulator of NMDA receptor (the principal excitatory glutamate ion channel involved in learning) signaling, and, chiefly as its sulfate ester DHEAS, as a negative allosteric modulator of the GABA-A receptor (the brain's main inhibitory ion channel). DHEA additionally behaves as a functional anti-glucocorticoid, buffering the neurotoxic effects of cortisol, and shows neuroprotective and mood-related activity in preclinical and clinical studies. Circulating concentrations peak in early adulthood and decline markedly with age, a phenomenon termed adrenopause that has driven its widespread use as an over-the-counter supplement.
Pregnanolone (3α-hydroxy-5β-pregnan-20-one, also written 3α,5β-tetrahydroprogesterone) is an endogenous neurosteroid, meaning a steroid that acts rapidly on neuronal ion channels rather than through classical intracellular hormone receptors, formed as a reduced metabolite of progesterone. It is the 5β epimer of allopregnanolone and a potent positive allosteric modulator of the GABA-A receptor (the pentameric chloride channel that carries most fast inhibitory signalling in the brain), giving it sedative, anxiolytic, anticonvulsant and anaesthetic properties. Under the International Nonproprietary Name eltanolone it was developed in the 1990s as an intravenous general anaesthetic, formulated in a soybean-oil emulsion after earlier castor-oil-solubilised steroid anaesthetics proved allergenic; smooth induction and cardiovascular stability were offset by slow recovery and skin reactions, and it was never marketed. Its sulfate and synthetic glutamate esters are studied separately as use-dependent inhibitors of the NMDA receptor, an excitatory glutamate channel implicated in excitotoxicity and neuroprotection.
Amantadine is an adamantane-derived drug that was first introduced in the 1960s as an antiviral agent against influenza A and later found, by chance, to relieve the symptoms of Parkinson's disease. Today it is used mainly in neurology, particularly to treat the involuntary movements (dyskinesias) that can arise from long-term levodopa therapy, while its role against influenza has largely disappeared because of viral resistance. It acts through a combination of dopaminergic and glutamatergic effects on the brain [1][2].
Dextromethorphan/bupropion is a fixed-dose combination medicine used to treat major depressive disorder in adults. Sold under the brand name Auvelity and developed by Axsome Therapeutics, it was approved by the United States Food and Drug Administration in 2022. The product pairs dextromethorphan, which blocks NMDA glutamate receptors and activates sigma-1 receptors, with bupropion, an established antidepressant that also slows the breakdown of dextromethorphan so that useful levels are maintained. It is taken as an extended-release oral tablet and is a prescription medicine that is not a controlled substance.
Progesterone (P4; pregn-4-ene-3,20-dione) is an endogenous pregnane steroid hormone best known for its reproductive roles and is the prototypical neuroactive precursor within the neurosteroid system. Although the parent hormone signals principally through classical nuclear progesterone receptors and through membrane-associated receptors such as PGRMC1 and the mPR/PAQR family, most of its rapid effects on neuronal excitability arise only after sequential metabolism to 5-alpha-dihydroprogesterone and then to allopregnanolone, one of the most potent endogenous positive allosteric modulators of the GABA-A receptor (the brain's principal inhibitory chloride channel). Progesterone and its metabolites are synthesized within the nervous system itself, where they regulate myelination, neuronal survival, neuroinflammation, and inhibitory tone. It has been studied extensively as a neuroprotective agent, with strong preclinical support but negative large-scale human trials in acute traumatic brain injury.
24(S)-Hydroxycholesterol (historically named cerebrosterol) is an endogenous oxysterol (an oxygenated derivative of cholesterol) generated almost exclusively in neurons by the enzyme cholesterol 24-hydroxylase (CYP46A1). It is the principal chemical route by which the brain, which cannot degrade cholesterol, exports its surplus; because the added hydroxyl group at carbon 24 allows the molecule to cross the blood-brain barrier (the selective interface between blood and brain tissue), plasma levels of 24(S)-hydroxycholesterol serve as an accessible marker of brain cholesterol turnover and neuronal mass. Beyond its housekeeping role, it is a bona fide neurosteroid; at physiological concentrations it acts as a potent positive allosteric modulator of N-methyl-D-aspartate (NMDA) receptors (a class of glutamate-gated ion channels central to learning and memory) and as an agonist of liver X receptors (LXR, nuclear receptors that govern lipid handling). Its pharmacology inspired the synthetic analog dalzanemdor (SAGE-718), an NMDA receptor positive allosteric modulator developed for cognitive impairment.
D-Cycloserine is a small molecule that acts as a partial agonist at the glycine co-agonist site of the NMDA glutamate receptor, and it is also a genuine antibiotic (used historically against tuberculosis). Because NMDA receptors are central to learning, it has been studied as an add-on to psychotherapy to enhance cognition and, in particular, fear extinction (the process of unlearning a fear). Its interest for the brain comes from gently boosting NMDA-dependent plasticity.
D-serine is the D-enantiomer of the amino acid serine and acts as a signaling molecule in the brain, where it serves as a co-agonist at the NMDA subtype of glutamate receptor. It is produced from L-serine by the enzyme serine racemase and is one of the more abundant D-amino acids in mammals, concentrated in regions such as the forebrain. Because NMDA receptors require a co-agonist alongside glutamate in order to open, glia-derived D-serine helps govern synaptic plasticity, learning, and memory; reduced D-serine signaling is central to the NMDA-hypofunction model of schizophrenia, in which serum levels are decreased, and it has also been investigated as an adjunct in major depression and as a predictor of response to ketamine.
DHEA sulfate (DHEAS) is the 3-beta sulfate ester of dehydroepiandrosterone and the most abundant circulating steroid in the human body, present in plasma at concentrations roughly a thousandfold higher than unconjugated DHEA. Synthesized principally in the zona reticularis of the adrenal cortex, it functions as a stable, long-lived reservoir that is interconverted with DHEA and supplies a precursor pool for downstream androgens and estrogens. Within the nervous system it is classified as a neurosteroid (a steroid synthesized in or acting directly upon nervous tissue); it acts as an agonist at the sigma-1 receptor (an intracellular chaperone protein), a positive modulator of the NMDA receptor (a glutamate-gated excitatory ion channel), and a negative allosteric modulator of the GABA-A receptor (the brain's principal inhibitory ion channel), giving it a net excitatory, pro-cognitive neuromodulatory profile. Circulating concentrations fall markedly with age, a decline termed adrenopause that has made DHEAS a widely studied biomarker of adrenal function, cognitive aging, and longevity.
Epiandrosterone (3β-hydroxy-5α-androstan-17-one; also called isoandrosterone) is an endogenous 5-alpha-reduced steroid formed from dehydroepiandrosterone (DHEA) and androstenedione, and it is the 3-beta-hydroxyl epimer of androsterone. It circulates in humans predominantly as its sulfate ester and functions as a weak neurosteroid (a steroid that acts on neuronal receptors rather than classical nuclear hormone receptors), producing only mild modulation of the GABA-A receptor (the brain's principal inhibitory chloride ion channel) while inhibiting glycine receptors (another inhibitory ligand-gated channel concentrated in the spinal cord and brainstem). Beyond the nervous system it is a well-characterized uncompetitive inhibitor of glucose-6-phosphate dehydrogenase (G6PD, the rate-limiting enzyme of the pentose phosphate pathway) and a recognized urinary marker of 5-alpha-reductase activity. Because it can be metabolized toward dihydrotestosterone (DHT, the most potent natural androgen), it is also sold over the counter as a non-methylated androgen prohormone.
Epipregnanolone (3beta-hydroxy-5beta-pregnan-20-one) is an endogenous neurosteroid and the fourth stereoisomer of tetrahydroprogesterone, distinguished from allopregnanolone (3alpha,5alpha), pregnanolone (3alpha,5beta), and sepranolone (3beta,5alpha) by its combined 3beta-hydroxyl group and 5beta (cis) ring fusion. It is a ring A-reduced metabolite of progesterone that, unlike the sedative potentiators allopregnanolone and pregnanolone, was classically characterized as a selective antagonist at the neurosteroid modulatory site of the GABA-A receptor (the brain's principal inhibitory ion channel), blocking their potentiation without altering the response to GABA itself. Its 3-sulfate ester is a negative allosteric modulator of the NMDA receptor (a glutamate-gated excitatory channel), and the parent steroid is also a potent blocker of CaV3.2 T-type calcium channels, giving it a profile that is unusually distinct from its potentiating sister isomers. Present at low concentrations in human plasma, especially around parturition, and producible by human gut bacteria, epipregnanolone is studied primarily as a pharmacological tool and a scaffold for neurosteroid drug design rather than as a therapeutic or supplement.
Gacyclidine (GK-11) is a phencyclidine derivative built for an entirely different job than PCP or ketamine ever had: not anesthesia or recreational dissociation, but neuroprotection after acute spinal cord injury. French chemist Jean-Marie Kamenka's PCP-analog work fed into development by Beaufour-Ipsen through the 1990s, producing a compound with roughly 100x higher affinity than PCP itself at the same NMDA channel binding site. It moved into human testing for acute spinal cord injury and was also explored for protecting the inner ear during cochlear trauma, while French defense-affiliated researchers separately studied it as a possible countermeasure for nerve-agent-induced seizures. Development for CNS trauma quietly stalled in the early 2000s as the whole NMDA-antagonist neuroprotectant class collapsed under disappointing trial results and psychotomimetic side effects, leaving gacyclidine as one of the more unusual dead ends in the ketamine/PCP family tree.
HA-966 is a small research-tool molecule, (±)-3-amino-1-hydroxypyrrolidin-2-one, that acts at the glycine co-agonist site of the NMDA glutamate receptor. It behaves as a partial agonist there, which in practice means it can dampen NMDA receptor activity (a functional antagonist) when the site is otherwise driven by glycine. It is used in labs to probe NMDA signaling rather than as a supplement.
Hemantane is a Russian aminoadamantane (a cage-shaped adamantane molecule carrying an amine group, the same chemical family as amantadine) developed at the Zakusov Institute of Pharmacology as an experimental antiparkinsonian and analgesic (pain-relieving) drug. It works through several linked actions at once: it is a low-affinity blocker of the NMDA glutamate receptor, it raises dopamine in the striatum, and it weakly and reversibly inhibits the enzyme MAO-B. It is essentially unknown outside Russian-language research and has no established use in Western medicine.
Ibogaine is a naturally occurring indole alkaloid derived from the root bark of the West African rainforest shrub Tabernanthe iboga, used traditionally in Bwiti spiritual ceremonies and studied since the 1960s for a striking property: a single large dose can interrupt opioid withdrawal and reduce drug craving for extended periods. It is a genuine polypharmacological agent, engaging NMDA glutamate receptors, kappa- and mu-opioid receptors, sigma-2 sites, the serotonin transporter, and alpha3beta4 nicotinic receptors simultaneously, and it is metabolized by CYP2D6 to the long-lived active metabolite noribogaine that is thought to mediate much of its anti-addictive action. A prominent hypothesis is that ibogaine and noribogaine upregulate glial cell line-derived neurotrophic factor (GDNF) in the midbrain, resetting reward circuitry after chronic drug exposure. These effects are counterbalanced by a serious cardiac liability: ibogaine blocks the hERG potassium channel, prolongs the QT interval, and has been associated with fatal ventricular arrhythmias. It is not an approved medicine and remains investigational.
NMDA (N-methyl-D-aspartic acid) is a synthetic amino-acid derivative that selectively activates one subtype of the brain's glutamate receptor; that receptor is named the NMDA receptor precisely because this molecule turns it on and nothing much else does. It is a laboratory and pharmacology research tool used to probe glutamate signaling, not a supplement or a nootropic to be taken. In animals and tissue it excites neurons and, at high exposure, can be excitotoxic (damaging through over-excitation).
Pregnenolone sulfate (PregS) is an endogenous excitatory neurosteroid (a steroid synthesized in and acting upon the nervous system) formed by sulfation of pregnenolone at its 3beta-hydroxyl group. It is among the most intensively studied neurosteroids in ion-channel pharmacology, acting simultaneously as a positive allosteric modulator of N-methyl-D-aspartate (NMDA) receptors that contain GluN2A or GluN2B subunits (the principal glutamate-gated channels underlying synaptic plasticity), a negative allosteric modulator of GABA-A receptors (the brain's main inhibitory chloride channels), a low-affinity agonist of the sigma-1 receptor (an intracellular chaperone protein) and the prototypical agonist of the TRPM3 cation channel. Through these convergent actions it enhances glutamatergic transmission, hippocampal acetylcholine release, long-term potentiation and memory consolidation in animal models, which underlies its reputation as a pro-cognitive neurosteroid. Its physiological concentrations, and even its unambiguous presence in mammalian brain, remain debated, so much of the evidence base derives from experimental administration rather than demonstrated endogenous signaling.
Dalzanemdor (SAGE-718) is a first-in-class, orally administered synthetic neuroactive steroid developed by Sage Therapeutics that acts as a positive allosteric modulator (a molecule that boosts a receptor's response without occupying its main agonist site) of the N-methyl-D-aspartate (NMDA) receptor, the principal excitatory glutamate-gated ion channel of the brain. It is a structural analog of the endogenous brain oxysterol 24(S)-hydroxycholesterol (24(S)-HC), a cholesterol metabolite that the same laboratory identified as a naturally occurring NMDA receptor PAM. The compound was advanced into clinical development for cognitive impairment associated with disorders thought to involve NMDA receptor hypofunction, including Huntington's disease, Parkinson's disease, and Alzheimer's disease. Its Phase 2 program, most notably the DIMENSION study in Huntington's disease, largely failed to meet primary cognitive endpoints during 2024 and 2025, after which Sage Therapeutics terminated the open-label Phase 3 PURVIEW study.
Traxoprodil (CP-101,606) started life at Pfizer in the 1990s as a stroke and traumatic-brain-injury neuroprotectant, built around a then-novel idea: block only the GluN2B (NR2B) subunit of the NMDA receptor instead of hammering the whole channel like PCP or MK-801. The stroke program stalled over QT-interval prolongation and hallucinations at neuroprotective doses, but the NR2B-selective mechanism looked too interesting to shelve. Pfizer repurposed it, and in a 2008 proof-of-concept study led by Sheldon Preskorn it relieved treatment-resistant major depression as an add-on therapy, one of the first solid human signals that NMDA blockade could work as an antidepressant outside of ketamine itself. But the same cardiac safety baggage that killed the stroke program followed it into psychiatry, and traxoprodil never advanced to Phase III for depression.
zelquistinel (codes GATE-251 and AGN-241751) is an investigational oral drug for depression; it is a positive allosteric modulator of the NMDA glutamate receptor, from the same 'rapastinel' lineage of NMDA-modulating antidepressants. the idea is a ketamine-style rapid and durable antidepressant effect via enhanced synaptic plasticity, but as a pill and without the dissociative high. it is not a classic pregnane neurosteroid; it is included as a glutamatergic modulator alongside them. it is in phase 2 testing for major depressive disorder.
Methadone is a synthetic opioid medication that acts mainly as an agonist at the mu-opioid receptor, with additional activity as an antagonist at the NMDA glutamate receptor. It is used both to treat opioid use disorder, where long-acting daily doses prevent withdrawal and reduce cravings, and to manage chronic and cancer pain. First synthesized in Germany in the late 1930s, methadone is distinguished among opioids by its long and variable duration of action, and it is listed as an essential medicine by the World Health Organization.